Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

ABSTRACT: Oral Microbiome in Alcohol Use Disorder during inpatient treatment

PROVIDER: PRJNA659632 | ENA |

REPOSITORIES: ENA

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	SRR12531302.fastq.gz	Fastqsanger.gz
	SRR12531303.fastq.gz	Fastqsanger.gz
	SRR12531304.fastq.gz	Fastqsanger.gz
	SRR12531305.fastq.gz	Fastqsanger.gz
	SRR12531306.fastq.gz	Fastqsanger.gz

Items per page:

1 - 5 of 90

Similar Datasets

Project description:Mizo Substance Use Disorder Oral Microbiome

| PRJNA1264526 | ENA

GDF15 in alcohol use disorder

Project description:GDF15 in alcohol use disorder Raw sequence reads

| PRJNA1366826 | ENA

Plasma TNFSF10B levels associated with acamprosate treatment response in patients with alcohol use disorder

Project description:Acamprosate is an anti-craving drug used in alcohol use disorder (AUD) pharmacotherapy. However, only a subset of patients achieves optimal treatment outcomes. The identification of predictive biomarkers of acamprosate treatment response in patients with AUD would be a substantial advance in addiction medicine. We designed this study to use proteomics data as a quantitative biological trait as a step toward identifying inflammatory modulators that might be associated with acamprosate treatment outcomes. The NIAAA-funded Mayo Clinic Center for the Individualized Treatment of Alcoholism study had previously recruited 442 AUD patients who received three months of acamprosate treatment. However, only 267 subjects returned for the 3-month follow-up visit and, as a result, had treatment outcome information available. Baseline alcohol craving intensity was the most significant predictor of acamprosate treatment outcomes. Baseline plasma TNFSF10 concentration was associated with alcohol craving intensity and variation in acamprosate treatment outcomes among AUD patients. We also performed RNA sequencing using baseline peripheral blood mononuclear cells from AUD patients with known acamprosate treatment outcomes which revealed that inflammation-related pathways were highly associated with relapse to alcohol use during the three months of acamprosate treatment. These observations represent an important step toward advancing our understanding of the pathophysiology of AUD and molecular mechanisms associated with acamprosate treatment response. In conclusion, applying omics-based approaches may be a practical approach for identifying biologic markers that could potentially predict alcohol craving intensity and acamprosate treatment response.

2022-09-21 | GSE208132 | GEO

Project description:Functional Microbial Responses to Alcohol Abstinence in Patients with Alcohol Use Disorder

| PRJNA613834 | ENA

Acamprosate, Craving and Alcohol Use Disorder: the Role of Inflammation

Project description:The present study utilized patient-derived “cell-line” model systems treated with anti-craving drugs that are used to treat alcohol use disorder (AUD) as “molecular probes” to help identify molecular mechanisms associated with craving and AUD treatment outcomes.

2024-04-03 | GSE213380 | GEO

Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

Project description:Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

| PRJNA729134 | ENA

Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

Project description:Epigenetic Moderators of Naltrexone Efficacy for Alcohol Use Disorder

| PRJNA729135 | ENA

human gut mycobiome

Project description:Human intestinal mycobiome in alcohol use disorder Targeted loci

| PRJNA703732 | ENA

Plasma TNFSF10B levels associated with acamprosate treatment response in patients with alcohol use disorder

Project description:Plasma TNFSF10B levels associated with acamprosate treatment response in patients with alcohol use disorder

| PRJNA858444 | ENA

Brief exposure to oral antibiotics has age-dependent effects on morphine reward and gene expression in the medial prefrontal cortex of adolescent and adult mice_1

Project description:Adolescence is a critical period for the initiation of problematic drug use, which significantly increases the risk of developing substance use disorders later in life. This heightened vulnerability is partly attributed to the immaturity of the prefrontal cortex, a brain region both essential for decision-making and implicated in drug reward. During adolescence, peripheral systems, such as the gut microbiome, also undergo substantial changes. Emerging evidence suggests that disruptions to the gut microbiome can influence gene expression and drug reward behaviors in rodent models. In this study, we investigated the effects of oral antibiotics on morphine reward and prefrontal cortical gene expression in adolescent and adult mice. Using oral antibiotics to transiently disrupt the microbiome, we found that short-term antibiotic exposure reduced morphine place preference specifically in adolescent mice. In a separate cohort, we observed that antibiotic treatment altered the transcriptomic response to morphine in the medial prefrontal cortex across all age groups. Notably, the transcriptomic changes induced by antibiotics and morphine were age-specific, with distinct gene expression patterns observed in adolescents compared to adults. These findings establish a foundation for future research into the role of the gut microbiome in opioid reward and highlight potential gene pathways underlying age-dependent differences in opioid sensitivity.

2025-08-01 | GSE303730 | GEO

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data